Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China

▤ Summary

Fangzhou launched Novo Nordisk’s once-weekly basal insulin/GLP-1 therapy, Kyinsu, on its Internet hospital platform in China. The company says this expands its collaboration with Novo Nordisk and strengthens access to innovative diabetes treatments through its AI-powered chronic disease management services. Fangzhou positions the launch as part of its broader AI+H2H ecosystem, which combines digital care, medication guidance, and ongoing patient support. The company also frames the release as a milestone for improving adherence and reducing the burden of daily insulin injections.

▦ Linked Companies